Cowen started coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX) in a report published on Tuesday morning, AR Network reports. The brokerage issued an outperform rating on the stock.
Separately, Piper Sandler assumed coverage on shares of Praxis Precision Medicines in a research report on Tuesday. They set an overweight rating and a $65.00 price target on the stock.
Shares of PRAX opened at $33.35 on Tuesday. Praxis Precision Medicines has a 1 year low of $23.90 and a 1 year high of $38.42.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.
Recommended Story: What are municipal bonds?
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.